onchocerciasis
Information
- Disease name
- onchocerciasis
- Disease ID
- DOID:11678
- Description
- "A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy." [url:http\://www.dpd.cdc.gov/dpdx/HTML/Filariasis.htm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03876262 | Active, not recruiting | Phase 3 | Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis | May 3, 2021 | July 2026 |
| NCT05180461 | Active, not recruiting | Phase 2 | Emodepside Phase II Trial for Treatment of Onchocerciasis | August 30, 2021 | October 2, 2026 |
| NCT00790998 | Completed | Phase 3 | Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection | April 2009 | May 2012 |
| NCT01905436 | Completed | Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia | March 2012 | July 2021 | |
| NCT02032043 | Completed | Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) | February 2014 | December 4, 2017 | |
| NCT02078024 | Completed | Phase 3 | Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana | June 2014 | June 25, 2018 |
| NCT03052998 | Completed | Phase 4 | Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy | October 1, 2017 | August 1, 2018 |
| NCT03131401 | Completed | Prevalence of LF Infection in Districts Not Included in LF Control Activities | January 21, 2018 | August 30, 2018 | |
| NCT03238131 | Completed | Phase 3 | IVM Alone vs ALB + IVM Against Onchocerciasis | April 2012 | October 2016 |
| NCT03517462 | Completed | N/A | Ocular Changes After Ivermectin - (DOLF IVM/Oncho) | August 6, 2018 | August 23, 2019 |
| NCT00127504 | Completed | Phase 2 | Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness | July 2003 | May 2004 |
| NCT00300768 | Completed | Phase 2 | Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection | September 6, 2006 | November 29, 2009 |
| NCT04188301 | Completed | Phase 2 | Safety and Efficacy of IDA for Onchocerciasis | December 6, 2019 | June 1, 2022 |
| NCT05749653 | Completed | N/A | Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area | March 1, 2017 | February 1, 2022 |
| NCT03962062 | Completed | Phase 1 | A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years | March 29, 2021 | September 28, 2022 |
| NCT05750043 | Completed | Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan | March 1, 2018 | February 19, 2023 | |
| NCT06070116 | Enrolling by invitation | Phase 2 | Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis | April 5, 2024 | September 1, 2026 |
| NCT06350851 | Not yet recruiting | N/A | Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination | April 2024 | April 2025 |
| NCT00001230 | Recruiting | Host Response to Infection and Treatment in Filarial Diseases | March 15, 1991 | ||
| NCT04311671 | Recruiting | Phase 3 | Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole | May 3, 2021 | July 2024 |
| NCT05084560 | Terminated | Phase 1 | Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug | December 10, 2021 | May 22, 2023 |
| NCT04913610 | Terminated | Phase 2 | Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection | May 29, 2021 | August 29, 2023 |
| NCT04035174 | Unknown status | N/A | Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa | September 1, 2022 | March 30, 2023 |
| NCT03653975 | Unknown status | Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District | October 2014 | May 2019 | |
| NCT01035619 | Withdrawn | Phase 2 | Pediatric Pharmacokinetics And Safety Study Of Moxidectin | April 2011 | April 2011 |
- Disase is a (Disease Ontology)
- DOID:1080
- Cross Reference ID (Disease Ontology)
- GARD:7252
- Cross Reference ID (Disease Ontology)
- ICD10CM:B73
- Cross Reference ID (Disease Ontology)
- ICD9CM:125.3
- Cross Reference ID (Disease Ontology)
- MESH:D009855
- Cross Reference ID (Disease Ontology)
- NCI:C34861
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:38539003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0029001
- Exact Synonym (Disease Ontology)
- Infection by Onchocerca volvulus
- Exact Synonym (Disease Ontology)
- Onchocerca volvulus infection
- Exact Synonym (Disease Ontology)
- volvulosis
- OrphaNumber from OrphaNet (Orphanet)
- 2737
- ICD10 preferred id (Insert disease from ICD10)
- D0000817
- ICD10 class code (Insert disease from ICD10)
- B73
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009855